Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fingolimod |
Synonyms | |
Therapy Description |
Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator that activates PP2A, which may result in restoration of tumor suppressor activity thereby leading to apoptosis and inhibition of cell proliferation (PMID: 24448818). Gilenya (fingolimod) is FDA approved for multiple sclerosis (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fingolimod | Gilenya | FTY720 | PP2A Activator 7 | Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator that activates PP2A, which may result in restoration of tumor suppressor activity thereby leading to apoptosis and inhibition of cell proliferation (PMID: 24448818). Gilenya (fingolimod) is FDA approved for multiple sclerosis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute lymphoblastic leukemia | sensitive | Fingolimod | Preclinical - Cell culture | Actionable | In a preclinical study, Gilenya (fingolimod) inhibited proliferation and induced cell death and cell cycle arrest in an acute lymphoblastic leukemia cell line harboring KMT2A rearrangement in culture (PMID: 37891368). | 37891368 |
KMT2A rearrange | acute myeloid leukemia | sensitive | Fingolimod | Preclinical - Cell culture | Actionable | In a preclinical study, Gilenya (fingolimod) inhibited proliferation and induced cell death and cell cycle arrest in an acute myeloid leukemia cell line harboring KMT2A rearrangement in culture (PMID: 37891368). | 37891368 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02490930 | Phase I | Fingolimod | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | Completed | USA | 0 |